Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-25

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers. Approximately half of the patients will have pancreatic cancer and the other half will have other cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines

NCT04379960

The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data

COMPLETED

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

NCT00389610

Pancreatic Cancer

COMPLETED PHASE2

Acelarin First Line Randomised Pancreatic Study

NCT03610100

Pancreatic Acinar Carcinoma Pancreatic Neoplasms

SUSPENDED PHASE2/PHASE3

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03387098

Pancreatic Cancer

TERMINATED PHASE1/PHASE2

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

NCT02004262

2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The immune system has an important role in helping prevent cancer by destroying early cancer cells. When cancer does develop antigen-specific immune (T) cells are still present in the blood but are either not responding or are not effective. Vaccines stimulate these T cells to respond and kill cancer cells.

ACIT-1 is designed to stimulate tumour antigen-specific T cells to respond and kill cancer cells.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immunotherapy - pancreatic cancer

Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.

Group Type EXPERIMENTAL

ACIT-1

Intervention Type BIOLOGICAL

Cell suspension

Immunotherapy - other late stage cancers

Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.

Group Type EXPERIMENTAL

ACIT-1

Intervention Type BIOLOGICAL

Cell suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACIT-1

Cell suspension

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed malignancy
* Life-expectancy of 3 months or greater
* Aged 18 years or above
* Willing and able to give written informed consent for participation in the study
* Eastern Cooperative Oncology Group performance status of 0,1,2.
* Absolute neutrophil count of ≥ 1 x 10e12/m3
* Platelet count of at least 70 x 10e12/m3
* Total bilirubin \< 1.5x upper limit of normal; and aspartate transaminase/alanine transaminase (AST/ALT) \< 5x upper limit of normal
* Creatinine \< 1.5x upper limit of normal and/or glomerular filtration rate (GFR) \> 40ml/min
* Female patients of child bearing potential and male patients whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter
* Normal ECG measurements
* Able (in the Investigators opinion) and willing to comply with all study requirements
* Willing to allow his or her General Practitioner (GP) and consultant, if appropriate, to be notified of participation in the study, and for the GP and/or the National Cancer Registry to be contacted during follow up after the end of treatment.

Exclusion Criteria

* Concurrent use of immunosuppressive drugs, in particular systemic steroid therapy, above a threshold of 10mg per day prednisolone equivalent
* Evidence of active infection e.g. Hepatitis B, Hepatitis C, HIV or syphilis
* Chemotherapy, radiotherapy or biological therapy within 28 days of treatment with the exception of standard of care chemotherapy for pancreatic and haematological cancer patients
* Participation in another investigational medicinal product trial within 28 days of treatment
* Other vaccination within previous 4 weeks
* Antibody treatment within previous 3 months
* Major surgery within the 14 days preceding the screening visit
* Scheduled elective surgery or other procedures requiring general anaesthesia during the study
* Allogeneic graft transplantation recipient
* Active systemic autoimmune and allergic disease
* Pregnant or lactating females
* Significant renal or hepatic impairment as defined by the following: Serum creatinine ≥ 1.5 x upper limit of normal and/or GFR ≤ 40 ml/min. Total bilirubin ≥ 1.5 x upper limit of normal; and AST/ALT ≥ 5 x upper limit of normal
* Life threatening illness unrelated to the patient's cancer
* Previous history of serious adverse allergic reaction to any medication
* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No